Autoimmune Thrombosis
Clinical research activity is centered on primary antiphospholipid syndrome, with interest in the immune-mediated mechanisms that drive recurrent clotting risk and systemic vascular complications.
- Antiphospholipid syndrome
- Autoantibody-related thrombosis
- Vascular inflammation
The sponsor’s current trial landscape reflects a focused commitment to rheumatology and hematology in a rare autoimmune disorder setting.
Immunomodulatory Therapy
Research interest includes the evaluation of anifrolumab in adults with primary antiphospholipid syndrome, indicating attention to immune-targeted treatment strategies in complex systemic disease.
- Biologic therapy
- Type I interferon pathway
- Immune-mediated disease control
This therapeutic area aligns with efforts to address inflammatory and autoimmune pathways relevant to thromboinflammatory disease.
Rare Disease Clinical Research
The sponsor is involved in a narrowly defined rare disease program focused on a single active study in Athens, supporting clinical investigation in an uncommon and medically challenging condition.
- Adult autoimmune disease
- Specialist-led clinical care
- Orphan disease research
Its research profile emphasizes disease-specific clinical evaluation within an academic medical environment.
